Chemed (NYSE:CHE) Lowered to “Strong Sell” Rating by Zacks Research

Chemed (NYSE:CHE) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group cut Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Royal Bank Of Canada reissued a “sector perform” rating and set a $422.00 target price (down from $572.00) on shares of Chemed in a research report on Friday, February 27th. Finally, Oppenheimer decreased their price target on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $498.00.

Chemed Stock Up 0.3%

NYSE:CHE opened at $412.36 on Wednesday. The stock has a market capitalization of $5.68 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 1.63 and a beta of 0.46. Chemed has a 52 week low of $385.00 and a 52 week high of $623.60. The firm has a 50 day moving average of $444.70 and a 200 day moving average of $443.11.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $6.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.02 by ($0.60). The business had revenue of $639.34 million for the quarter, compared to analyst estimates of $659.09 million. Chemed had a return on equity of 25.66% and a net margin of 10.48%.The business’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the previous year, the company posted $6.83 earnings per share. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. As a group, analysts expect that Chemed will post 21.43 EPS for the current year.

Institutional Trading of Chemed

A number of hedge funds and other institutional investors have recently made changes to their positions in CHE. Monetary Solutions Ltd acquired a new position in Chemed during the fourth quarter valued at $25,000. Los Angeles Capital Management LLC purchased a new position in shares of Chemed during the 4th quarter valued at about $26,000. Smartleaf Asset Management LLC lifted its holdings in shares of Chemed by 71.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock valued at $27,000 after buying an additional 25 shares during the period. BOK Financial Private Wealth Inc. acquired a new stake in Chemed during the fourth quarter worth about $27,000. Finally, First Horizon Corp acquired a new stake in Chemed during the third quarter worth about $31,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.